Results 21 to 30 of about 1,361 (136)

Safety, pharmacokinetics, and clinical activity of adavosertib in combination with chemotherapy in Asian patients with advanced solid tumors : Phase Ib study [PDF]

, 2020
Background: The WEE1 inhibitor adavosertib (AZD1775) has been investigated in Western patients. Objective: This open-label Phase Ib study (NCT02341456) investigated the safety, pharmacokinetics, and clinical activity of adavosertib in combination with ...
Kato, Hidenori, Naito, Yoichi, Mugundu, Ganesh M., Lickliter, Jason D., de Souza, Paul, Kumar, Sanjeev, Park, Keunchil, Souza, Paul de (R16678), Kim, Sang-We, Bang, Yung-Jue   +9 more
core   +1 more source

Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia [PDF]

, 2023
\ua9 2023, BioMed Central Ltd., part of Springer Nature. Background: Outcomes for patients with relapsed acute lymphoblastic leukemia (ALL) are poor and there is a need for novel therapies to improve outcomes.
Irving JAE, Blair HJ, Lunec J, Moorman AV, Singh M, Bell HL, van Delft FW, Heidenreich O   +7 more
core   +6 more sources

Codelivery of adavosertib and olaparib by tumor-targeting nanoparticles for augmented efficacy and reduced toxicity

Acta Biomaterialia, 2023
Ovarian cancer (OC) ranks first among gynecologic malignancies in terms of mortality. The benefits of poly (ADP-ribose) polymerase (PARP) inhibitors appear to be limited to OC with BRCA mutations. Concurrent administration of WEE1 inhibitors (eg, adavosertib (Ada)) and PARP inhibitors (eg, olaparib (Ola)) effectively suppress ovarian tumor growth ...
Wei Wang, Yuxuan Xiong, Xingyuan Hu, Funian Lu, Tianyu Qin, Li Zhang, Ensong Guo, Bin Yang, Yu Fu, Dianxing Hu, JunPeng Fan, Xu Qin, Chen Liu, RouRou Xiao, Gang Chen, Zifu Li, Chaoyang Sun   +16 more
openaire   +2 more sources

Transcriptionally distinct malignant neuroblastoma populations show selective response to adavosertib treatment. [PDF]

Neurotherapeutics
Neuroblastoma is an aggressive childhood cancer that arises from the sympathetic nervous system. Despite advances in treatment, high-risk neuroblastoma remains difficult to manage due to its heterogeneous nature and frequent development of drug resistance. Drug repurposing guided by single-cell analysis presents a promising strategy for identifying new
Hsieh CH, Chen YX, Tseng TY, Li A, Huang HC, Juan HF.   +5 more
europepmc   +3 more sources

Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian carcinoma [PDF]

, 2022
BACKGROUND. A double-blind, randomized, placebo-controlled, phase 2 trial assessed gemcitabine in combination with the wee1 inhibitor adavosertib or placebo in platinum resistant or refractory high grade serous ovarian cancer (HGSOC), demonstrating ...
Wang, Lisa, Kavak, Nisan, Mitchell, Sandra A., Dhani, Neesha C, Chang, Karen, Karakasis, Katherine, Quintos, Judy, Welch, Stephen A., Madariaga, Ainhoa, Ramsahai, Janelle, Welch, Stephen A, Bowering, Valerie, Oza, Amit M, Pittman, Tyler, Dhani, Neesha C., Lheureux, Stephanie, Oza, Amit M., Mitchell, Sandra A   +17 more
core   +1 more source

Transcription termination counteracts DNA damage after WEE1 inhibition. [PDF]

Nucleic Acids Res
Transcription termination is a key regulatory step in transcription and a potential target for cancer therapy, but how it can be exploited for treatment is incompletely understood.
Landsverk HB, Sandquist LE, Bay LTE, Hauge S, van Bijsterveldt L, Lindbergsengen L, Lund-Andersen C, Kanduri C, Lyng H, Fjeldbo CS, Hompland T, Humphrey TC, Syljuåsen RG.   +12 more
europepmc   +2 more sources

Ricolinostat enhances adavosertib‑induced mitotic catastrophe in TP53‑mutated head and neck squamous cell carcinoma cells

International Journal of Oncology, 2022
TP53 mutation is one of the most frequent gene mutations in head and neck squamous cell carcinoma (HNSCC) and could be a potential therapeutic target. Recently, the WEE1 G2 checkpoint kinase (WEE1) inhibitor adavosertib (Adv) has attracted attention because of its selective cytotoxicity against TP53‑mutated cells and has shown promising activity in ...
Miyake, Keitaro, Takano, Naoharu, Kazama, Hiromi, Kikuchi, Hiroyuki, Hiramoto, Masaki, Tsukahara, Kiyoaki, Miyazawa, Keisuke   +6 more
openaire   +2 more sources

Comprehensive multi-omics analyses expose a precision therapy strategy that targets replication stress in hepatocellular carcinoma using WEE1 inhibition. [PDF]

J Adv Res
Introduction: Hepatocellular carcinoma (HCC) is an extremely heterogeneous malignancy with a poor prognosis, highlighting the need to target specific vulnerabilities within the tumor during treatment.
Jia X, Zhu X, Chen S, Qiu Q, Song W, Zhang S, Dong H, Li Z, Bian S, Wu H, Dai H, Jin C, Zhou M, Chen J, Xuan Z, Liu P, Zeng Q, Xie H, Zheng S, Song P.   +19 more
europepmc   +2 more sources

Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study

, 2021
Purpose: This study assessed the efficacy, safety, and pharmacokinetics of adavosertib in combination with four chemotherapy agents commonly used in patients with primary platinum-resistant ovarian cancer.
Cadoo, Karen A, Mugundu, Ganesh M, Kumar, Sanjeev, Cragun, Janiel M, Spigel, David R, Rodrigo Imedio, Esteban, Moore, Kathleen N, Hamilton, Erika P, Konecny, Gottfried E, Plaxe, Steven C, Lai, Zhongwu, Oza, Amit M, Ghamande, Sharad A, Troso-Sandoval, Tiffany A, Jones, Suzanne F, Chambers, Setsuko K, Spitz, Daniel L, Geenen, Jill J J, Chen, Lee-May, Chmielecki, Juliann   +19 more
core   +1 more source

The role of Wee1 and Myt1 in breast cancer [PDF]

, 2020
To ensure faithful cell division, entry into mitosis must be inhibited in cells with damage or under-replicated DNA. Wee1 and Myt1 are two partially redundant kinases that inhibit mitotic entry through the phosphorylation of the Cdk1/cyclin B complex ...
Lewis, Cody Wayne
core   +1 more source